Also in the neoadjuvant setting, the S0800 phase II safety and efficacy trial evaluated bevacizumab with nab-paclitaxel 100 mg/m2 weekly followed by dose-dense AC with pegfilgrastim, compared with nonbevacizumab arms containing nab-paclitaxel followed or preceded by dose-dense AC with pegfilgrastim, in patients with HER2-negative inflammatory or locally advanced BC [37]. This evidence concerns the gene ERBB2 and breast cancer.